DBH deficiency in an elderly patient: efficacy and safety of chronic droxidopa.
We describe the effects of chronic droxidopa in a patient with Dopamine beta-hydroxylase deficiency diagnosed at the age of 73. Investigations were performed to assess sympathetic activity (MIBG scintigraphy, catecholamines) and cardiovascular droxidopa safety.
Despas
Fabien
F
INSERM U858 équipe 8, 31432 Toulouse, France. fabien.despas@yahoo.fr
Pathak
A
A
Berry
M
M
Cagnac
R
R
Massabuau
P
P
Liozon
E
E
Galinier
M
M
Senard
J M
JM
D019797:3-Iodobenzylguanidine; D000368:Aged; D001342:Autonomic Nervous System Diseases / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000201:enzymology*; D002395:Catecholamines / Q000097:blood; D004299:Dopamine beta-Hydroxylase / Q000172:deficiency*; D015103:Droxidopa / Q000627:therapeutic use*; D006801:Humans; D007024:Hypotension, Orthostatic / Q000150:complications; D008297:Male; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals
D002395:Catecholamines; D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine; D004299:Dopamine beta-Hydroxylase; D015103:Droxidopa